Y-mAbs Therapeutics to Highlight Advances at Industry Conference
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a dynamic biopharmaceutical entity dedicated to developing groundbreaking radioimmunotherapy and antibody-based treatments for cancer, is gearing up for a vital event. Michael Rossi, the Company’s President and Chief Executive Officer, has confirmed his participation in an engaging fireside chat at the 35th Annual Life Sciences Conference hosted by Oppenheimer.
Key Details of the Conference
The communication will take place at 4:40 p.m. ET. An opportunity for broader engagement through a live webcast will be accessible in the Events section of Y-mAbs' investor relations website, which means that even those unable to attend the event live can catch up later, as the webcast will be available for replay for 30 days following the discussion.
What Sets Y-mAbs Apart
Y-mAbs is not just another biopharmaceutical company; it is at the forefront of innovation in cancer treatment. The company's approach revolves around advanced technologies, including its investigational Self-Assembly DisAssembly ("SADA") Pretargeted Radioimmunotherapy Platform ("PRIT") and the Y-BiClone platform for generating bispecific antibodies. This unique combination allows Y-mAbs to develop a broad, advanced pipeline of cancer therapies.
Innovative Cancer Therapies in Development
Among the promising therapies in its portfolio is DANYELZA® (naxitamab-gqgk). This groundbreaking treatment has garnered attention as the first FDA-approved option for patients suffering from relapsed or refractory high-risk neuroblastoma affecting the bone or bone marrow following previous treatments. With such advancements, Y-mAbs aims to improve the landscape of cancer treatment significantly.
Engaging with the Investor Community
Y-mAbs recognizes the importance of investor engagement, especially during crucial industry events. By participating in forums like the Oppenheimer Annual Life Sciences Conference, the Company not only showcases its progress but also builds connections with stakeholders who are eager to learn more about innovative treatments for cancer.
The Future of Cancer Therapy
While the Company focuses on immediately relevant therapies, the broader implications of their innovative research are what truly resonate. By utilizing cutting-edge methodologies, Y-mAbs is positioned to play a significant role in the advancement of cancer treatment options, ideally paving the way for enhanced patient outcomes.
Company Contact Information
For those interested in learning more or seeking additional information, the investor contact for Y-mAbs is Courtney Dugan, who serves as the Vice President and Head of Investor Relations. She can be reached via email at cdu@ymabs.com.
Frequently Asked Questions
What is the focus of Y-mAbs Therapeutics?
Y-mAbs Therapeutics concentrates on developing innovative radioimmunotherapies and antibody-based treatments to combat cancer.
When will the fireside chat be held?
The fireside chat will take place at 4:40 p.m. ET during the Oppenheimer 35th Annual Life Sciences Conference.
How can I access the conference webcast?
You can find the live webcast in the Events section of Y-mAbs' investor relations website, where it will also be available for 30 days after the event.
What notable product is in Y-mAbs' pipeline?
DANYELZA® (naxitamab-gqgk) is a key product in Y-mAbs' pipeline, recognized for its FDA approval for a specific cancer patient population.
Who should I contact for more information about Y-mAbs?
You can contact Courtney Dugan, VP of Investor Relations, via email at cdu@ymabs.com.
